Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665504 · ClinicalTrials.gov registry record
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
A clinical trial of Adenocarcinoma of Lung and Lung; Node, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT05665504 is a study of Adenocarcinoma of Lung and Lung; Node that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 250 participants, above the 123-participant average among 5 other Adenocarcinoma of Lung trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05665504, a study of Adenocarcinoma of Lung and Lung; Node, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST DetermaRX
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2028-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665504
The ClinicalTrials.gov registry entry for NCT05665504 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 5 other Adenocarcinoma of Lung trials with a reported enrollment target (103% higher). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenocarcinoma of Lung appearing as the primary indexed condition, and to 1 intervention - of which DetermaRX is the first listed.
NCT05665504 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05665504 about?
NCT05665504 is a clinical study titled "Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer". This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identif...
What is the current status of trial NCT05665504?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2023-01-11. Estimated completion is 2028-02.
What conditions does trial NCT05665504 study?
This clinical trial studies the following conditions: Adenocarcinoma of Lung, Lung; Node.
What interventions are being tested in trial NCT05665504?
The interventions under investigation include: DetermaRX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05665504?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05665504 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
RECRUITING · Phase 2
-
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
RECRUITING · Phase 1
-
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
RECRUITING · Phase 2
-
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.